In vivo Laser-induced Fluorescence Imaging of a Rat Pancreatic Cancer with Pheophorbide-a

1997 ◽  
Vol 65 (6) ◽  
pp. 997-1006 ◽  
Author(s):  
V. Tassetti ◽  
A. Hajri ◽  
M. Sowinska ◽  
S. Evrard ◽  
F. Heisel ◽  
...  
2003 ◽  
Vol 7 (6) ◽  
pp. 765-773 ◽  
Author(s):  
Severine Wack ◽  
Amor Hajri ◽  
Francine Heisel ◽  
Malgorzata Sowinska ◽  
Cedric Berger ◽  
...  

2015 ◽  
Vol 3 (14) ◽  
pp. 2873-2882 ◽  
Author(s):  
Jianhua Shen ◽  
Yunfeng Li ◽  
Yihua Zhu ◽  
Xiaoling Yang ◽  
Xiuzhong Yao ◽  
...  

Gd-labeled, peptide-conjugated Fe3O4 NPs and fluorescent CuInS2 QDs were fabricated for imaging of pancreatic cancer.


2010 ◽  
Vol 999 (999) ◽  
pp. 1-11
Author(s):  
P. Ulivi ◽  
C. Arienti ◽  
W. Zoli ◽  
M. Scarsella ◽  
S. Carloni ◽  
...  

2009 ◽  
Vol 17 (5) ◽  
pp. 1442-1452 ◽  
Author(s):  
Roderich E. Schwarz ◽  
Niranjan Awasthi ◽  
Srivani Konduri ◽  
Danielle Cafasso ◽  
Margaret A. Schwarz

Biology ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 610
Author(s):  
Robin Park ◽  
Andrew L. Coveler ◽  
Ludimila Cavalcante ◽  
Anwaar Saeed

Glycogen synthase kinase-3 beta is a ubiquitously and constitutively expressed molecule with pleiotropic function. It acts as a protooncogene in the development of several solid tumors including pancreatic cancer through its involvement in various cellular processes including cell proliferation, survival, invasion and metastasis, as well as autophagy. Furthermore, the level of aberrant glycogen synthase kinase-3 beta expression in the nucleus is inversely correlated with tumor differentiation and survival in both in vitro and in vivo models of pancreatic cancer. Small molecule inhibitors of glycogen synthase kinase-3 beta have demonstrated therapeutic potential in pre-clinical models and are currently being evaluated in early phase clinical trials involving pancreatic cancer patients with interim results showing favorable results. Moreover, recent studies support a rationale for the combination of glycogen synthase kinase-3 beta inhibitors with chemotherapy and immunotherapy, warranting the evaluation of novel combination regimens in the future.


Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 930
Author(s):  
Donatella Delle Cave ◽  
Riccardo Rizzo ◽  
Bruno Sainz ◽  
Giuseppe Gigli ◽  
Loretta L. del Mercato ◽  
...  

Pancreatic cancer, the fourth most common cancer worldwide, shows a highly unsuccessful therapeutic response. In the last 10 years, neither important advancements nor new therapeutic strategies have significantly impacted patient survival, highlighting the need to pursue new avenues for drug development discovery and design. Advanced cellular models, resembling as much as possible the original in vivo tumor environment, may be more successful in predicting the efficacy of future anti-cancer candidates in clinical trials. In this review, we discuss novel bioengineered platforms for anticancer drug discovery in pancreatic cancer, from traditional two-dimensional models to innovative three-dimensional ones.


Author(s):  
Pengrui Zhuang ◽  
Ke Xiang ◽  
Xiangxi Meng ◽  
Guohe Wang ◽  
Ziyuan Li ◽  
...  

A facile and green method was developed to fabricate Nd-DTPA on a large scale without byproducts for CT/spectral CT and NIR II fluorescence imaging of the gastrointestinal tract in vivo.


Pancreatology ◽  
2020 ◽  
Author(s):  
Lisi Peng ◽  
Lu Zhuang ◽  
Kun Lin ◽  
Yao Yao ◽  
Yang Zhang ◽  
...  
Keyword(s):  

2021 ◽  
Author(s):  
Bo Sun ◽  
Xu Zhen ◽  
Xiqun Jiang

This review mainly introduced the MSNs-based nanoprobes for in vivo bioimaging applications including fluorescence imaging and photoacoustic imaging.


Sign in / Sign up

Export Citation Format

Share Document